NASDAQ:OPHT - Ophthotech Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ophthotech Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.78 +0.09 (+1.35 %) (As of 01/19/2020 10:28 AM ET) Add Compare Today's Range$6.62Now: $6.78▼$6.9250-Day Range$1.13MA: $1.30▼$1.3952-Week Range$1.02Now: $6.78▼$4.50Volume555,161 shsAverage Volume159,109 shsMarket Capitalization$280.83 millionP/E RatioN/ADividend YieldN/ABeta1.49 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPHT Previous Symbol CUSIPN/A CIK1410939 Webhttp://www.ophthotech.com/ Phone212-845-8200Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$209.98 million Price / Sales1.34 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book2.26Profitability EPS (Most Recent Fiscal Year)($1.67) Net Income$63.09 million Net MarginsN/A Return on Equity-141.53% Return on Assets-41.88%Miscellaneous Employees35 Outstanding Shares41,420,000Market Cap$280.83 million Next Earnings DateN/A OptionableOptionable Receive OPHT News and Ratings via Email Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter. Ophthotech (NASDAQ:OPHT) Frequently Asked Questions What is Ophthotech's stock symbol? Ophthotech trades on the NASDAQ under the ticker symbol "OPHT." How were Ophthotech's earnings last quarter? Ophthotech Corp (NASDAQ:OPHT) announced its quarterly earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.02. View Ophthotech's Earnings History. Has Ophthotech been receiving favorable news coverage? Media coverage about OPHT stock has been trending positive this week, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ophthotech earned a news impact score of 2.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Ophthotech. Who are some of Ophthotech's key competitors? Some companies that are related to Ophthotech include Affimed (AFMD), Theratechnologies (THTX), Advanz Pharma (CXRXF), Cerecor (CERC), Aeglea Bio Therapeutics (AGLE), Ocular Therapeutix (OCUL), Tyme Technologies (TYME), LifeVantage (LFVN), Chiasma (CHMA), GlycoMimetics (GLYC), XOMA (XOMA), IDEAYA Biosciences (IDYA), Athersys (ATHX), Fortress Biotech (FBIO) and Bicycle Therapeutics (BCYC). What other stocks do shareholders of Ophthotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ophthotech investors own include iShares US Preferred Stock ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Celgene (CELG) and Alibaba Group (BABA). Who are Ophthotech's key executives? Ophthotech's management team includes the folowing people: Dr. David R. Guyer, Exec. Chairman (Age 59)Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44) What is Ophthotech's stock price today? One share of OPHT stock can currently be purchased for approximately $6.78. How big of a company is Ophthotech? Ophthotech has a market capitalization of $280.83 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $63.09 million in net income (profit) each year or ($1.67) on an earnings per share basis. Ophthotech employs 35 workers across the globe.View Additional Information About Ophthotech. What is Ophthotech's official website? The official website for Ophthotech is http://www.ophthotech.com/. How can I contact Ophthotech? Ophthotech's mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected] MarketBeat Community Rating for Ophthotech (NASDAQ OPHT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 362 (Vote Outperform)Underperform Votes: 304 (Vote Underperform)Total Votes: 666MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of investing in REITs?